Pharma Services
Pharma Services
联系我们
contact us
Address of Medical Laboratory:
2/F, Building A28, Life Science Industrial Park, Dapeng New District, Shenzhen
Customer Service Email:
neoservice@yucebio.com
Service Hotline:
0755-22741310
400-9958-139
TEL:
+86 13632641856
Website:
www.yucebio.com
Company Profile

Shenzhen Yuce Neoantigen Technology Co., Ltd. ("YuceNeo") is a wholly-owned subsidiary of Shenzhen YuceBio Technology Co., Ltd. It relies on the international leading neoantigen predication technology platform, the largest Chinese tumor immunotherapy real-world data platform and the multi-omics research and translation platform centering on immune cycles to provide one-stop solution for the development of tumor immunotherapy drugs, including CDx development, central lab test, biomarker development, tumor immunotherapy data mining, neoantigen prediction and validation, and patient recruitment services.

Quality and Compliance

We have 1500 square meters of modern medical laboratory space (including PCR, NGS, pathology and cell platforms, etc.) in Shenzhen Dapeng Biological Valley. The medical laboratory has CAP certification and ISO9001 on-site certification. A clinical biology analysis and experimental center that meets the GLP/GCP standards has been established, which can provide biological sample analysis services at all stages of clinic studies. We have a 3000 square meter GMP production workshop in Taizhou that meets the requirements of GSP management regulations.

0.5.png


Management Team
Zhibo Gao
Founder & CEO

Ph.D. in Medical Science, Chinese University of Hong Kong, and COP student of China Europe International Business School

Former Director of the Department of Gene Medicine Research and Head of Cancer Bioinformatics Team of BGI

Member of the International Cancer Genome Consortium (ICGC) and core member of the Chinese Cancer Genome Consortium (CCGC)

Published many academic papers as the co-first author on journals including Nature and Science;

In March 2017, Dr. Gao and many top oncologists in China jointly launched the "Ladder for Cancer Moonshot".

Ernest Su
General Manager of SVP & YuceNeo

Ph.D in Internal Medicine, School of Medicine, Xi'an Jiaotong University

Former Head of Diagnostic Medicine and Business Development Department of Simcere

Head of Medical and Clinical Business Department, and Deputy General Manager of KingMed Diagnostics Group

Intermediate and senior management positions such as the Head of Respiratory Medicine Team at AstraZeneca

More than 10 years of experience in pharmaceutical and precision medicine industries

Jiaxi Wang
Director of Bioinformation and Data Science

·Former BGI Senior Bioinformation Engineer

·Participated in the China Cancer Genome Project (CCGC), International Cancer

·Genome Program (ICGC), National 863 High-Tech Program Eesophageal Cancer

·Tumor Neoantigen Screening Alliance (TESLA), etc


Shengqiang Xu
Director of the Experimental R & D Department

·Postdoctoral fellow at the Center for Biomedical Engineering, Michigan State University

·CSC National Public Study Program Harvard Medical School-Harbin University of Technology

·Member of the American Society of Neurobiology and the World Society of Medical Imaging


Top